Exceptional roundup - the saline spray data is something I wish more doctors talked about. That 20% reductoin in sick days from the Lancet trial is pretty compelling, especially given how low-risk and cheap the intervention is. Always found it odd that somthing this straightforwrd gets overlooked while more complex treatments get pushed. The ReBoost contamination issue really underlines why regulatory oversight matters even for OTC stuff.
Exceptional roundup - the saline spray data is something I wish more doctors talked about. That 20% reductoin in sick days from the Lancet trial is pretty compelling, especially given how low-risk and cheap the intervention is. Always found it odd that somthing this straightforwrd gets overlooked while more complex treatments get pushed. The ReBoost contamination issue really underlines why regulatory oversight matters even for OTC stuff.
So true! Simple but effective. Thank you for the comments.